$CATX (PERSPECTIVE THERAPEUTICS) — 8-K: Perspective Therapeutics inks Merck collaboration to test PSV359 with Keytruda in FAP-α solid tumors

Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors. The combination will be tested under an amendment to the ongoing Phase 1/2a study (NCT06710756) in non-small cell lung cancer and colorectal cancer. The study has completed enrollment in the first three monotherapy dose cohorts. Perspective sponsors the study, and Merck provides pembrolizumab at no cost.

Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab) i